Navigation Links
Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
Date:7/8/2009

LA JOLLA, Calif., and BARCELONA, July 8 /PRNewswire/ -- Fate Therapeutics, Inc. announced today the presentation of data from its research on small molecule modulators of the Wnt pathway for osteo-regeneration at the 7th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Barcelona, Spain. In its findings, the Company demonstrated that selected Wnt activators induce the differentiation of mesenchymal stem cells to mature, bone-forming osteoblasts. The study highlights the potential for using small molecule Wnt activators as osteogenic agents. Because osteogenic agents stimulate positive bone growth, they may offer an improved course of action in clinical settings ranging from orthopedics to osteoporosis as compared to current medications aimed at preventing bone decay.

"By applying our knowledge of adult stem cell biology to mesenchymal stem cell populations, we have identified osteogenic small molecules that can direct lineage-specific differentiation to an osteoblast phenotype," said Paul Grayson, president and CEO of Fate Therapeutics. "While current therapies focus on blocking bone degeneration, novel small molecules that promote bone formation represent the next-generation of therapeutic agents for osteo-regenerative medicine."

Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem cell (iPSC) technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes. Naturally-occurring adult stem cells, such as mesenchymal stem cells, can differentiate into a variety of cell types and are found in almost all tissues or organs in the body where they are primarily responsible for maintaining and repairing their native tissue. The ability of SCMs to promote bone regeneration may be applied to treat a number of bone injuries and conditions including non-union fracture, spinal fusion or osteoporosis.

The Company's poster entitled, "A small molecule activator of the canonical Wnt pathway stimulates differentiation of mesenchymal stem cells to an osteoblast phenotype," will be presented by Scott Thies, Ph.D., senior director of stem cell biology at Fate Therapeutics, at ISSCR on Friday, July 10 from 4:45 p.m. to 7:00 p.m. CEST.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... physical therapy provider for Derby City CrossFit, effective immediately. , In addition to ... and effectively as possible, ProRehab’s sports physical therapists will work with athletes to ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are now ... fear and require sedation to receive dental care. The doctors offer three treatment options ... hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... -- Halo Labs announces the launch of a novel ... the Horizon at PEGS 2017 in Boston ... sub visible particulate matter in biopharmaceutical samples to enable ... as candidate selection and pre-formulation. Halo Labs ... Elion Labs for system validation. "We are ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: